- Home
- LFST vs APLS Comparison
LFST vs APLS Comparison
Compare LFST & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFST | APLS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LFST | APLS |
|---|---|---|
| Price | $7.07 | $21.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $8.83 | ★ $33.21 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $1,367,570,000.00 | $1,016,397,000.00 |
| Revenue This Year | $15.75 | $28.88 |
| Revenue Next Year | $14.36 | N/A |
| P/E Ratio | ★ N/A | $61.40 |
| Revenue Growth | 13.39 | ★ 42.11 |
| 52 Week Low | $3.74 | $16.10 |
| 52 Week High | $8.30 | $30.80 |
Technical Indicators
Market Signals| Indicator | LFST | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 42.69 |
| Support Level | $7.02 | $19.26 |
| Resistance Level | $7.37 | $22.24 |
| Average True Range (ATR) | 0.23 | 1.40 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 15.00 | 25.52 |
Price Performance
Historical ComparisonAbout LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.